— Know what they know.
Not Investment Advice

PXS.L LSE

Provexis plc
1W: +15.0% 1M: -8.6% 3M: -23.2% YTD: -36.0% 1Y: +33.3% 3Y: +53.6% 5Y: +6.7%
£0.86 ($0.01)
-0.10 (-10.42%)
 
Weekly Expected Move ±9.5%
£1 £1 £1 £1 £1
LSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 40 · £22.5M mcap · 1.81B float · 0.056% daily turnover

Income Trends

Revenue
$1M +105.7% ▲
5Y CAGR: +30.0%
Gross Profit
$533K -3.6% ▼
5Y CAGR: +11.3%
Operating Income
-$448K -43.4% ▼
Net Income
-$453K -52.2% ▼
EPS (Diluted)
$-0.00 -50.0% ▼
EBITDA
-$450K +0.0% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$505K$426K$390K$802K$1M
YoY Growth+45.2%-15.7%-8.5%+105.7%—
Cost of Revenue$49K$46K$95K$518K$759K
Gross Profit$456K$380K$294K$284K$533K
Gross Margin90.3%89.2%75.5%35.4%41.2%
R&D Expenses$304K$250K$237K$302K$326K
SG&A Expenses$380K$430K$438K$465K$491K
Operating Expenses$818K$676K$715K$887K$985K
Operating Income-$362K-$299K-$421K-$604K-$448K
Operating Margin-71.6%-70.2%-108.0%-75.3%-34.7%
Interest Expense$0$0$0$0$0
Income Before Tax-$362K-$299K-$420K-$602K-$450K
Tax Expense-$2K-$59K-$33K-$14K$3K
Net Income-$341K-$224K-$385K-$586K-$453K
Net Margin-67.5%-52.6%-98.8%-73.1%-35.0%
EPS (Diluted)$-0.00$-0.00$-0.00$-0.00$-0.00
EBITDA$0$0$0-$604K-$450K
Shares Outstanding2.10B2.21B2.22B2.22B2.28B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms